Open AccessmiR-214 sensitizes human colorectal cancer cells to doxorubicin by p53 targeting
Publication year - 2020
Publication title -
iranian red crescent medical journal
Language(s) - English
Resource type - Journals
ISSN - 2074-1804
DOI - 10.32592/ircmj.2020.22.12.226
Subject(s) - transfection , apoptosis , doxorubicin , flow cytometry , medicine , colorectal cancer , viability assay , mtt assay , cancer research , cancer cell , microrna , cancer , cell culture , chemotherapy , biology , immunology , gene , biochemistry , genetics
Objectives: This study aimed to investigate the potential function of miR-214 in the apoptosis induction by targeting p53 in human colorectal cancer cells (CRC) in combination with doxorubicin (DOX). Methods: miR-214 mimics were transfected to HT-29 CRC cells. Following that, the transfected cells were treated with DOX. Cell viability, apoptosis, and migration were evaluated by MTT, flow cytometry, and scratch-wound motility assays, respectively. Furthermore, the expression level of miR-214 and p53 was evaluated by qRT-PCR. Results: miR-214 transfection significantly inhibited the cell proliferation rate (P<0.05), induced apoptosis (P<0.05), and harnessed migration (P<0.05) in the HT-29 cells after 48 h. Furthermore, more effectiveness was observed in combination with DOX. Additionally, miR-214 transfection led to a reduction in p53 expression offering that it might be a potential target for miR-214. Conclusion: In conclusion, miR-214 sensitizes HT-29 cells to doxorubicin by targeting p53 indicating the significant role of this miRNA in colorectal cancer chemotherapy.